TCB-2 is a hallucinogen discovered in 2006 by Thomas McLean working in the lab of David Nichols at Purdue University. It is a conformationally-restricted derivative of the phenethylamine 2C-B, also a hallucinogen, and acts as a potent agonist for the 5-HT2A and 5-HT2C receptors with a Ki of 0.26 nM at the human 5-HT2A receptor.
In drug-substitution experiments in rats, TCB-2 was found to be of similar potency to both LSD and Bromo-DragonFLY, ranking it among the most potent phenethylamine hallucinogens yet discovered. This high potency and selectivity has made TCB-2 useful for distinguishing 5-HT2A receptor-mediated responses from those produced by other similar receptors.
TCB-2 has similar but not identical effects in animals to related phenethylamine hallucinogens such as DOI, and has been used for studying how the function of the 5-HT2A receptor differs from that of other serotonin receptors in a number of animal models, such as studies of cocaine addiction and neuropathic pain. It has also been found to produce rapid antidepressant-, anti-anhedonic-, and anxiolytic-like effects in animals.
See also
- β-Methyl-2C-B
- 2CB-Ind
- 2CBCB-NBOMe
- Ivabradine
- Jimscaline
- LPH-5 (drug)
- S33005
- ZC-B
References
(1).png)
